Article    Table of Contents                    Full Text of this article Free    PDF of this article    Figures/Tables List  Services    Send comment/rapid response letter    Notify a friend about this article    Alert me when this article is cited    Add to Personal Archive    Download to Citation Manager    ACP Search    Get Permissions  Google Scholar    Search for Related Content  Social Bookmarking

What's this?

PubMed

Articles in PubMed by Author:    Kolaczynski, J. W.    Caro, J. F.    Related Articles in PubMed    PubMed Citation    PubMed

REVIEW

Insulin-like Growth Factor-1 Therapy in Diabetes: Physiologic Basis, Clinical Benefits, and Risks

Jerzy W. Kolaczynski, MD, and Jose F. Caro, MD

1 January 1994 | Volume 120 Issue 1 | Pages 47-55

Purpose: To review the effects of insulin-like growth factor-1 (IGF-1) and to discuss the clinical benefits and risks of using it in patients with diabetes.

Data Sources: Recent publications identified through a MEDLINE search using relevant keywords.

Study Selection: Selected studies on the metabolic effects and kinetic mechanisms of in vitro IGF-1 and existing literature on the effects of IGF-1 on glucose and lipid metabolism in vivo with special emphasis on data from humans.

Data Synthesis: The substantial stimulatory effect of IGF-1 on glucose uptake suggests that, in selected clinical situations, the drug may be an alternative to standard treatment of diabetes. Metabolic control in patients with extreme insulin resistance is improved after using IGF-1. Moreover, patients with type II (non-insulin-dependent) diabetes who receive IGF-1 have improved glucose tolerance and decreased hyperinsulinemia and hypertriglyceridemia. The complications associated with long-term administration of IGF-1 are unknown but might include the progression of certain neoplasms and diabetic complications, such as nephropathy and retinopathy.

Conclusions: Insulin-like growth factor-1 may be a useful adjunct for treatment of diabetes and may even be the drug of choice in some patients with extreme insulin resistance who have metabolic emergencies. However, further data are needed to evaluate the risks and benefits of IGF-1 use in diabetes and in other states associated with impaired insulin action.

Author and Article Information

From the Department of Medicine, Jefferson Medical College, Thomas Jefferson University, Philadelphia, Pennsylvania.
Requests for Reprints: Jose F. Caro, MD, Department of Medicine, Jefferson Medical College, College Building, Suite 821, 1025 Walnut Street, Philadelphia, PA 19107-5083.
Acknowledgments: The authors thank Drs. Barry Goldstein, Marshall Goldberg, and Robert Considine for careful review of the manuscript; Drs. Gary G. Carpenter and Ewa Surmacz for valuable discussions; and Mrs. Francine Holak for preparation of figures and Mrs. Diane Miller for the typing of the manuscript.
Grant Support: In part by grant RO1 DK45592 from the National Institute of Health.

CiteULike

Complore

Connotea

Del.icio.us

Digg

Facebook

Reddit

Technorati

Twitter

This article has been cited by other articles:

				S. Pellitero, J. L Reverter, M. L. Granada, E. Pizarro, M C. Pastor, D. Tassies, J. C. Reverter, I. Salinas, and A. Sanmarti Association of the IGF1/pregnancy-associated plasma protein-A system and adipocytokine levels with the presence and the morphology of carotid plaques in type 2 diabetes mellitus patients with stable glycaemic control Eur. J. Endocrinol., June 1, 2009; 160(6): 925 - 932. [Abstract] [Full Text] [PDF]

				E. Conti, C. Carrozza, E. Capoluongo, M. Volpe, F. Crea, C. Zuppi, and F. Andreotti Insulin-Like Growth Factor-1 as a Vascular Protective Factor Circulation, October 12, 2004; 110(15): 2260 - 2265. [Full Text] [PDF]

				Y.-J. Y. Wan, G. Han, Y. Cai, T. Dai, T. Konishi, and A.-S. Leng Hepatocyte Retinoid X Receptor-{alpha}-Deficient Mice Have Reduced Food Intake, Increased Body Weight, and Improved Glucose Tolerance Endocrinology, February 1, 2003; 144(2): 605 - 611. [Abstract] [Full Text] [PDF]

				A. M. Fernandez, J. K. Kim, S. Yakar, J. Dupont, C. Hernandez-Sanchez, A. L. Castle, J. Filmore, G. I. Shulman, and D. Le Roith Functional inactivation of the IGF-I and insulin receptors in skeletal muscle causes type 2 diabetes Genes & Dev., August 1, 2001; 15(15): 1926 - 1934. [Abstract] [Full Text] [PDF]

				W.-L. Lee, J.-W. Chen, C.-T. Ting, T. Ishiwata, S.-J. Lin, M. Korc, and P. H. Wang Insulin-Like Growth Factor I Improves Cardiovascular Function and Suppresses Apoptosis of Cardiomyocytes in Dilated Cardiomyopathy Endocrinology, October 1, 1999; 140(10): 4831 - 4840. [Abstract] [Full Text]

				A. K. Berfield, D. Spicer, and C. K. Abrass Insulin-like Growth Factor I (IGF-I) Induces Unique Effects in the Cytoskeleton of Cultured Rat Glomerular Mesangial Cells J. Histochem. Cytochem., April 1, 1997; 45(4): 583 - 594. [Abstract] [Full Text] [PDF]

				D. Le Roith Insulin-Like Growth Factors N. Engl. J. Med., February 27, 1997; 336(9): 633 - 640. [Full Text] [PDF]

				E. Wolf, P. M. Jehle, M. M. Weber, H. Sauerwein, A. Daxenberger, B. H. Breier, U. Besenfelder, L. Frenyo, and G. Brem Human Insulin-Like Growth Factor I (IGF-I) Produced in the Mammary Glands of Transgenic Rabbits: Yield, Receptor Binding, Mitogenic Activity, and Effects on IGF-Binding Proteins Endocrinology, January 1, 1997; 138(1): 307 - 313. [Abstract] [Full Text] [PDF]

				X.-J. Liu, Q. Xie, Y.-F. Zhu, C. Chen, and N. Ling Identification of a Nonpeptide Ligand That Releases Bioactive Insulin-like Growth Factor-I from Its Binding Protein Complex J. Biol. Chem., August 24, 2001; 276(35): 32419 - 32422. [Abstract] [Full Text] [PDF]